Publications

1. Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer

   The National Health Care Institute has completed its assessment of abemaciclib (Verzenios®) for the treatment of metastatic ...

   Report | 07-03-2019

2. Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL)

   The National Health Care Institute carried out an assessment of the medicinal product axicabtagene ciloleucel (axi-cel, ...

   Report | 07-03-2019

3. Tisagenlecleucel (Kymriah®) for the treatment of DLBCL

   The National Health Care Institute has completed its assessment of tisagenlecleucel (Kymriah®) for the treatment of DLBCL. Due to ...

   Report | 07-03-2019

4. Rivaroxaban (Xarelto®) for the prevention of atherothrombotic complications in adult patients with coronary artery disease

   The National Health Care Institute carried out an assessment of medicinal product rivaroxaban (Xarelto®). The manufacturer ...

   Report | 04-03-2019

5. Patiromer (Veltassa®) for the treatment of hyperkalaemia in adults

   The National Health Care Institute has carried out an assessment whether patiromer (Veltassa®) is interchangeable with a ...

   Report | 25-02-2019

6. GVS assessment of evolocumab (Repatha®) for the treatment of primary hypercholesterolaemia

   The National Health Care Institute carried out a reassessment of the medicinal product Evolocumab (Repatha®) for the treatment of ...

   Report | 23-01-2019

7. Tisagenlecleucel-T (Kymriah®) for the treatment of ALL

   The National Health Care Institute carried out an assessment of the medicinal product tisagenlecleucel-T (Kymriah®) for the ...

   Report | 18-12-2018

8. Lesinurad (Zurampic®) for the treatment of hyperuricaemia in gout patients

   The National Health Care Institute carried out an assessment whether lesinurad (Zurampic®) is interchangeable with any product ...

   Report | 04-12-2018

9. Letermovir (Prevymis®) in cases of adult CMV-seropositive recipients of an allogenic haemotopoietic stem cell transplant (HSCT)

   The National Health Care Institute has carried out an assessment whether letermovir (Prevymis®) is interchangeable with a ...

   Report | 27-11-2018

10. Final report FAIR Data feasibility assessment

    This is the final report of the FAIR Data part of the FAIR Data and Personal Health Train feasibility assessment. In this ...

    Report | 31-10-2018